ChemicalBook >> CAS DataBase List >>KB-0742 dihydrochloride

KB-0742 dihydrochloride

CAS No.
2416874-75-2
Chemical Name:
KB-0742 dihydrochloride
Synonyms
KB-0742 dihydrochloride;KB0742,inhibit,CDK,CDK9,KB-0742,KB 0742,Ser7,Ser2,CRPC,KB 0742 dihydrochloride,antiproliferative,Cyclin dependent kinase,Ser5,oral,Inhibitor,KB0742 dihydrochloride,anticancer
CBNumber:
CB09624184
Molecular Formula:
C16H26ClN5
Molecular Weight:
323.87
MDL Number:
MFCD32899897
MOL File:
2416874-75-2.mol
Last updated:2023-05-21 10:59:17

KB-0742 dihydrochloride Properties

storage temp. 4°C, away from moisture
solubility |DMSO : 62.5 mg/mL (173.45 mM; Need ultrasonic)
Water Solubility Water : 100 mg/mL (277.52 mM; Need ultrasonic)

KB-0742 dihydrochloride Chemical Properties,Uses,Production

Biological Activity

KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity[1]. KB-0742 (6 hours; 0.1-10 μM; 22Rv1 cells) treatment significant reduction of downstream phosphorylation of RNA Pol II at Ser2 and Ser7, and diminished phosphorylation at Ser5. Global androgen receptor (AR)-FL and AR-V protein levels are significantly reduced starting at 6 h treatment time, which is accompanied by the reduction of phospho-AR levels (Ser81)[1].KB-0742 (48-72 hours) treatment shows cytostatic effects in prostate cancer and leukemia cell lines. KB-0742 shows antiproliferative activity with GR50s of 0.183 μM and 0.288 μM for 22Rv1 cells and MV-4-11 AML cells, respectively[1].In 22Rv1 cells, KB-0742 rapidly downregulates nascent transcription, preferentially depleting short half-life transcripts and AR-driven oncogenic programs[1]. KB-0742 (3-30 mg/kg; p.o.; daily; over 21 days) is well tolerated even at high dose, while significantly reducing tumor burden in 22Rv1 human prostate cancer cell line-derived xenograft (CDX) models[1].

References

[1]. André Richters, et al. Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2020 Oct 20;S2451-9456(20)30380-9.

KB-0742 dihydrochloride Preparation Products And Raw materials

Raw materials

Preparation Products

KB-0742 dihydrochloride Suppliers

Global( 15)Suppliers
Supplier Tel Email Country ProdList Advantage
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10523 58
Nantong HI-FUTURE Biology Co., Ltd.
+undefined18051384581 sales@chemhifuture.com China 3136 58
TargetMol Chemicals Inc.
+1-781-999-5354 support@targetmol.com United States 19973 58
LEAPCHEM CO., LTD.
+86-852-30606658 market18@leapchem.com China 43348 58
Aladdin Scientific
+1-833-552-7181 sales@aladdinsci.com United States 52927 58
ShangHai Caerulum Pharma Discovery Co., Ltd. 18149758185 sales-cpd@caerulumpharma.com China 3423 58
Shanghai Rechem science Co., Ltd. 21-31433387 15618786686 sales@rechemscience.com China 2989 58
Chuzhou KeMail Chemical Technology Co., Ltd 0550-5196001 15000891977 wj520wjxby@126.com China 1836 55
Shandong Jirun Biomedical Technology Co., Ltd. 0539-0539-8613587 17661611089 2639273505@qq.com China 163 58
Nantong Hi-Future Biotechnology Co., Ltd 18051384581 sales@chemhifuture.com China 3061 58
KB-0742 dihydrochloride KB0742,inhibit,CDK,CDK9,KB-0742,KB 0742,Ser7,Ser2,CRPC,KB 0742 dihydrochloride,antiproliferative,Cyclin dependent kinase,Ser5,oral,Inhibitor,KB0742 dihydrochloride,anticancer 2416874-75-2